A study has shown that adenovirus vaccine injection into the tumoral lesions of cutaneous T-cell lymphoma leads to tumor reduction by the induction of interferon gamma, a subtype 1 helper T (Th1) cell cytokine [9]. The gene discussed is IFNG; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.